Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor‐positive breast cancer

2021 ◽  
Author(s):  
Heather M. Brechbuhl ◽  
Mengyu Xie ◽  
Etana G. Kopin ◽  
Amy L. Han ◽  
Kiran Vinod‐Paul ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Endocrine Therapy ◽  
Poor Prognosis ◽  
Neoadjuvant Endocrine Therapy ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

scholarly journals Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

JAMA Oncology ◽  
2016 ◽  
Vol 2 (11) ◽  
pp. 1477 ◽  
Author(s):  
Laura M. Spring ◽  
Arjun Gupta ◽  
Kerry L. Reynolds ◽  
Michele A. Gadd ◽  
Leif W. Ellisen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Endocrine Therapy ◽  
Neoadjuvant Endocrine Therapy ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients – an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pathobiological response of the patients

2012 ◽  
Vol 27 (4) ◽  
pp. 295-304 ◽  
Author(s):  
Monica Sm Chan ◽  
Lin Wang ◽  
Saulo Ja Felizola ◽  
Takayuki Ueno ◽  
Masakazu Toi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Endocrine Therapy ◽  
Stromal Cells ◽  
Breast Cancer Patients ◽  
Neoadjuvant Endocrine Therapy ◽  
Ki 67 ◽  
Before And After ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

Tumor-stromal interactions involve continuous crosstalk and interactions among different cell types and play pivotal roles in tumorigenesis, tumor development, disease progression, subsequent metastasis, and also tumor response to therapeutic agents. Tumor infiltrating lymphocytes (TILs) are important components of these tumor-stromal interactions. Specific TIL subtypes are known to be involved in the clinical course of individual patients. However, the status of TILs following endocrine therapy has not been studied in breast cancer patients. We evaluated the alterations of TIL subtypes in a cohort of East Asian patients with estrogen receptor-positive breast cancer during the course of neoadjuvant steroidal aromatase inhibitor (AI) therapy, using double immunohistochemical staining of CD8+ and T regulatory cells (Treg) or Foxp3+, yielding the CD8+/Treg ratio in individual patients. Changes in CD8+/Treg ratio before and after therapy were then correlated with pathobiological responses of individual patients based upon alterations of the Ki-67 labeling index (LI). A significant increase in the CD8+/Treg ratio was detected in responders (p=0.028) but not in non-responders, which may reflect the dynamic process in which the host immune response to tumor antigens changed in consequence of an interaction between tumor and stromal cells in its microenvironment following estrogen depletion caused by the AI. The CD8+/Treg ratio in breast cancer tissue can be a potential surrogate marker in surgical pathology specimens for predicting responses to neoadjuvant endocrine therapy, not only incorporating features of carcinoma cells as in Ki-67 LI but also those of adjacent stromal cells in the tumor microenvironment, especially in the early stage of treatment prior to any detectable clinical and/or histopathological changes.

scholarly journals Neoadjuvant endocrine therapy for estrogen receptor-positive primary breast cancer

2020 ◽  
Vol 9 (3) ◽  
pp. 30-30
Author(s):  
Yutaka Yamamoto ◽  
Lisa Goto-Yamaguchi ◽  
Masako Takeno ◽  
Mutsuko Yamamoto-Ibusuki
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Endocrine Therapy ◽  
Primary Breast Cancer ◽  
Neoadjuvant Endocrine Therapy ◽  
Estrogen Receptor Positive
Sign in / Sign up

Export Citation Format

Share Document